Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 81

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 81
---
 Change

    2025

    2024

    ($)

    %

    Operating
    expenses:

    Research
    and development
     
    $
    6,495,677

    $
    4,771,152

    $
    1,724,525

    36.1
    %
  
    General
    and administrative

    5,182,132

    6,423,029

    (1,240,897
    )

    (19.3
    )%

    Total
    operating expenses

    11,677,809

    11,194,181

    483,628

    4.3
    %

    Loss
    from operations

    (11,677,809
    )

    (11,194,181
    )

    (483,628
    )

    4.3
    %

    Other
    income, net

    94,764

    303,201

    (208,437
    )

    (68.7
    )%
  
    Change
    in fair value of convertible promissory notes

    (1,153,421
    )

    -

    (1,153,421
    )

    100
    % 

    Net
    loss
     
    $
    (12,736,466
    )
     
    $
    (10,890,980
    )
     
    $
    (1,845,486
    )

    16.9
    %
  
    Net
    loss attributable to common stockholders per share, basic and diluted
     
    $
    (18.48
    )
     
    $
    (34.53
    )
     
    $
    16.05

    (46.5
    )%
  
    Weighted
    average number of shares used in calculating net loss per share, basic and diluted

    689,174

    315,451

Research
and Development Expenses

Research
and development expenses were approximately $6.5 million for the nine months ended September 30, 2025, compared to approximately
$4.8 million for the nine months ended September 30, 2024, representing an increase of approximately $1.7 million, or 36.1%. The
increase was primarily driven by higher clinical trial costs of approximately $2.